vs
LivaNova PLC（LIVN）与Streamex Corp.（STEX）财务数据对比。点击上方公司名可切换其他公司
Streamex Corp.净利率更高（155840.0% vs 8.6%，领先155831.4%）。过去两年Streamex Corp.的营收复合增速更高（NaN% vs NaN%）
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
LIVN vs STEX — 直观对比
营收规模更大
LIVN
是对方的-36092.1倍
$-10.0K
净利率更高
STEX
高出155831.4%
8.6%
两年增速更快
STEX
近两年复合增速
10.6%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $360.9M | $-10.0K |
| 净利润 | $30.9M | $-15.6M |
| 毛利率 | 65.2% | — |
| 营业利润率 | 11.8% | 61130.0% |
| 净利率 | 8.6% | 155840.0% |
| 营收同比 | 12.1% | — |
| 净利润同比 | -44.7% | -714.2% |
| 每股收益（稀释后） | $0.57 | $-0.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LIVNSTEX
| Q4 25 | $360.9M | — | ||
| Q3 25 | $357.8M | $-10.0K | ||
| Q2 25 | $352.5M | $13.0K | ||
| Q1 25 | $316.9M | — | ||
| Q4 24 | $321.8M | $13.0K | ||
| Q3 24 | $318.1M | $0 | ||
| Q2 24 | $318.6M | $13.0K | ||
| Q1 24 | $294.9M | $14.0K |
净利润LIVNSTEX
| Q4 25 | $30.9M | — | ||
| Q3 25 | $26.8M | $-15.6M | ||
| Q2 25 | $27.2M | $-20.4M | ||
| Q1 25 | $-327.3M | — | ||
| Q4 24 | $55.9M | $-1.1M | ||
| Q3 24 | $33.0M | $-1.9M | ||
| Q2 24 | $16.3M | $-3.9M | ||
| Q1 24 | $-41.9M | $-3.4M |
毛利率LIVNSTEX
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — | ||
| Q1 24 | 70.3% | — |
营业利润率LIVNSTEX
| Q4 25 | 11.8% | — | ||
| Q3 25 | 15.1% | 61130.0% | ||
| Q2 25 | 15.4% | -156653.8% | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 11.5% | -9100.0% | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 12.6% | -40707.7% | ||
| Q1 24 | 5.5% | -24550.0% |
净利率LIVNSTEX
| Q4 25 | 8.6% | — | ||
| Q3 25 | 7.5% | 155840.0% | ||
| Q2 25 | 7.7% | -156707.7% | ||
| Q1 25 | -103.3% | — | ||
| Q4 24 | 17.4% | -8453.8% | ||
| Q3 24 | 10.4% | — | ||
| Q2 24 | 5.1% | -30115.4% | ||
| Q1 24 | -14.2% | -24300.0% |
每股收益（稀释后）LIVNSTEX
| Q4 25 | $0.57 | — | ||
| Q3 25 | $0.49 | $-0.47 | ||
| Q2 25 | $0.50 | $-0.74 | ||
| Q1 25 | $-6.01 | — | ||
| Q4 24 | $1.04 | $0.03 | ||
| Q3 24 | $0.60 | $-0.12 | ||
| Q2 24 | $0.30 | $-0.30 | ||
| Q1 24 | $-0.78 | $-0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.6M | — |
| 总债务越低越好 | $376.1M | — |
| 股东权益账面价值 | $1.2B | $-7.0M |
| 总资产 | $2.6B | $130.5M |
| 负债/权益比越低杠杆越低 | 0.31× | — |
8季度趋势，按日历期对齐
现金及短期投资LIVNSTEX
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | — | ||
| Q2 25 | $593.6M | — | ||
| Q1 25 | $738.4M | — | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | — | ||
| Q2 24 | $329.2M | — | ||
| Q1 24 | $309.2M | — |
总债务LIVNSTEX
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
股东权益LIVNSTEX
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $-7.0M | ||
| Q2 25 | $1.1B | $-3.6M | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.3B | $-1.5M | ||
| Q3 24 | $1.3B | $-405.0K | ||
| Q2 24 | $1.2B | $-6.0K | ||
| Q1 24 | $1.2B | $-4.3M |
总资产LIVNSTEX
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | $130.5M | ||
| Q2 25 | $2.5B | $109.7M | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.5B | $842.0K | ||
| Q3 24 | $2.5B | $1.4M | ||
| Q2 24 | $2.5B | $3.1M | ||
| Q1 24 | $2.5B | $1.6M |
负债/权益比LIVNSTEX
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.4M | $-5.0M |
| 自由现金流经营现金流 - 资本支出 | $50.2M | — |
| 自由现金流率自由现金流/营收 | 13.9% | — |
| 资本支出强度资本支出/营收 | 8.9% | — |
| 现金转化率经营现金流/净利润 | 2.67× | — |
| 过去12个月自由现金流最近4个季度 | $173.3M | — |
8季度趋势，按日历期对齐
经营现金流LIVNSTEX
| Q4 25 | $82.4M | — | ||
| Q3 25 | $85.1M | $-5.0M | ||
| Q2 25 | $62.9M | $-1.3M | ||
| Q1 25 | $24.0M | — | ||
| Q4 24 | $78.7M | $-474.0K | ||
| Q3 24 | $51.0M | $-1.5M | ||
| Q2 24 | $43.4M | $-1.5M | ||
| Q1 24 | $10.0M | $-1.3M |
自由现金流LIVNSTEX
| Q4 25 | $50.2M | — | ||
| Q3 25 | $62.2M | — | ||
| Q2 25 | $47.8M | — | ||
| Q1 25 | $13.2M | — | ||
| Q4 24 | $68.3M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $31.2M | — | ||
| Q1 24 | $3.6M | — |
自由现金流率LIVNSTEX
| Q4 25 | 13.9% | — | ||
| Q3 25 | 17.4% | — | ||
| Q2 25 | 13.6% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 21.2% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 1.2% | — |
资本支出强度LIVNSTEX
| Q4 25 | 8.9% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 3.4% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 2.2% | — |
现金转化率LIVNSTEX
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
STEX
暂无分部数据
